Daptomycin Pharmacokinetics in Critically Ill Patients undergoing Extracorporeal Membrane Oxygenation

Daptomycin Pharmacokinetics in Critically Ill Patients undergoing Extracorporeal Membrane Oxygenation: a Prospective Study

Status

Active, not recruiting

Phases

Early Phase 1

Study type

Observational

Source

ChiCTR

Registry ID

ChiCTR2100052422

Enrollment

Unknown

Registered

2021-10-25

Start date

2017-02-04

Completion date

Unknown

Last updated

2022-10-17

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Bloodstream infection

Interventions

ECMO group:Nil

Non ECMO group:Nil

Eligibility

Sex/Gender

All

Age

18 Years to 85 Years

Inclusion criteria

Inclusion criteria: 1. Aged >= 18 years; 2. Stay in ICU; 3. Use VA-ECMO or VV-ECMO; 4. Diagnosis of bloodstream infection with drug-resistant positive bacteria; 5. Sign informed consent.

Exclusion criteria

Exclusion criteria: 1. Pulmonary infection with positive bacteria; 2. Have been treated with daptomycin in the past 7 days; 3. Estimated survival time < 24h; 4. Pregnancy; 5. Malignant tumor; 6. Patients who participated in other studies within 30 days.

Design outcomes

Primary

Measure	Time frame
Pharmacokinetics;	—

Countries

China

Contacts

Public ContactHuang Yingzi

Zhongda Hospital Affiliated to Southeast University

yz_huang@126.com+86 13951693278

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026